Therini Bio Inc.
- Address
- 2108 N Street Suite 4963
Sponsor Overview
Specializations
Neurodegenerative disease research
Therini Bio Inc. is involved in clinical research focused on Alzheimer’s disease, with attention to early-stage patient populations and the evaluation of therapies intended for central nervous system disorders.
- Alzheimer’s disease
- Early-stage neurodegeneration
- Central nervous system therapeutics
The sponsor’s work in this area reflects interest in disease-modifying approaches for cognitive decline and related neurological impairment.
Healthy volunteer studies
The company also supports clinical research in healthy volunteers, indicating an interest in establishing basic human safety and tolerability data for investigational therapies.
- Healthy subjects
- Safety assessment
- Tolerability
This area provides a human research foundation for understanding how candidate treatments behave in participants without diagnosed disease.
Pharmacokinetic and drug safety evaluation
Therini Bio Inc. funds studies centered on pharmacokinetics, with emphasis on how investigational agents are processed in the body alongside their safety and tolerability profiles.
- Pharmacokinetics
- Safety
- Tolerability
These research interests are relevant to early clinical development of therapies intended for neurological conditions.
Randomized and placebo-controlled clinical investigation
The sponsor’s clinical portfolio includes controlled human studies designed to compare investigational therapy with placebo in carefully monitored settings.
- Randomized clinical research
- Placebo-controlled studies
- Blinded assessment
These studies support evaluation of therapeutic signals in both neurologically affected participants and healthy individuals.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase I Double-Blind, Randomized, Placebo-Controlled Study on Safety, Tolerability, and Pharmacokinetics of THN391 in Healthy Volunteers |  The Netherlands | Not Recruiting |
| Safety, Tolerability, and Pharmacokinetics of THN391 in Early Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Phase 1b Study | The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 3 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
3 centres- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Hanzeplein 1, 9713 GZ Groningen
- Address
- Van Swietenlaan 6, 9728 NZ Groningen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Therini Bio Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.